The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
Activities Underway to Support Planned Commercial Expansion Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and
Webcast to Commence at 7:15 p.m. CT / 8:15 p.m. ET , Saturday, November 10, 2018 BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members
BEDMINSTER, N.J. and DUBLIN, Ireland , Oct. 19, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), announced today that its wholly owned subsidiary, Corsicanto II Designated Activity Company, a designated activity company with limited liability incorporated under the laws
BEDMINSTER, N.J. and DUBLIN, Ireland , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F.
REDUCE-IT Is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific to Pure EPA Vascepa at 4 Grams Daily Conference Call Scheduled for Today, Monday, September 24, 2018 at
Topline Results of the REDUCE-IT Study Anticipated Before End of September 2018 BEDMINSTER, N.J. and DUBLIN, Ireland , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve
REDUCE-IT is the First Study of Any Therapy to Prospectively Enroll and Evaluate Risk Reduction for Cardiovascular Events in Statin-Treated Patients with Elevated Triglyceride Levels and Other Cardiovascular Risk Factors REDUCE-IT Study Remains On-Track for Report of Top-Line Results Before the End
Management to Host Conference Call at 8:00 a.m. ET August 27, 2018 to Discuss Data Presented at European Society of Cardiology Congress BEDMINSTER, N.J. and DUBLIN, Ireland , Aug. 25, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the